Last April, the FDA ordered compounding pharmacies to stop producing copycat weight-loss drugs, but sales have continued
Comparacin directa entre dos GLP-1 oral ACHIEVE-3 proporciona los primeros datos de comparacin directa entre dos frmacos GLP-1 oral en diabetes tipo 2, en los que orforglipron ha mostrado mayores reducciones de HbA1c y peso que semaglutida oral en las dosis aprobadas para diabetes, afirm el Julio Rosenstock, profesor clnico de Medicina en el Centro Mdico Southwestern de la Universidad de Texas e investigador principal de ACHIEVE-3
Achieving these outcomes with a second obesity medication may indicate a broader efficacy trend for pairing these two classes of medications." Menopause-related hormonal changes often result in increased abdominal fat, decreased muscle mass and altered energy expenditure that leads to weight gain and puts millions of women at risk for developing heart disease and other serious health issues
From enhancing cardiovascular health to improving insulin sensitivity and promoting mental well-being, Semaglutide offers a comprehensive approach to health that addresses multiple facets of chronic disease management
Andrew Huberman: They're not motivated enough to come in as research subjects
